- Report
- November 2023
- 139 Pages
Global
From €2398EUR$2,499USD£2,065GBP
- Report
- June 2023
- 280 Pages
Global
From €2399EUR$2,500USD£2,066GBP
- Report
- September 2023
- 180 Pages
Global
From €5709EUR$5,950USD£4,917GBP
- Report
- January 2024
- 175 Pages
Global
From €4797EUR$5,000USD£4,132GBP
- Report
- January 2024
- 206 Pages
Global
From €3486EUR$3,633USD£3,002GBP
€4980EUR$5,190USD£4,289GBP
- Report
- July 2022
- 155 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Report
- June 2022
- 320 Pages
Global
From €13337EUR$13,900USD£11,487GBP
- Report
- January 2022
- 200 Pages
Global
From €7196EUR$7,500USD£6,198GBP
- Clinical Trials
- July 2020
- 268 Pages
Global
From €2399EUR$2,500USD£2,066GBP
Choroidal Neovascularization (CNV) is a condition in which abnormal blood vessels grow beneath the retina in the eye. It is a major cause of vision loss in age-related macular degeneration (AMD). Optical treatments for CNV include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to destroy the abnormal blood vessels and prevent further vision loss. Photodynamic therapy uses a light-activated drug to destroy the abnormal vessels. Anti-VEGF injections are used to block the growth of new vessels and reduce fluid leakage.
The CNV market is highly competitive, with a number of companies offering treatments and products. These include Novartis, Regeneron, Allergan, Roche, Bayer, and Santen Pharmaceuticals. Show Less Read more